The Institute for Clinical and Economic Review on Thursday, Dec. 13, announced a planned evaluation of the comparative clinical effectiveness and value of treatments for Duchenne muscular dystrophy (DMD).
ICER says the assessment will spotlight Sarepta Therapeutics’ eteplirsen and golodirsen. While eteplirsen received Food and Drug Administration approval in September 2016, the agency is expected to approve golodirsen some time in 2019.
An open input period began Thursday, and comments will be accepted until 5 p.m. EST Jan. 8.
A draft scoping document on the planned review will be available Jan. 11, and will be open for public comment for three weeks, according to a press release.
To read the full press release, click here.